Avacopan Delivery Through Feeding Tube for Severe Vasculitis
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a new way to deliver avacopan—a drug that reduces inflammation in rare blood vessel diseases (ANCA-associated vasculitis)—through a feeding tube instead of by mouth. The study measures how much of the drug reaches your bloodstream and checks if it's safe for patients with very severe disease who are on a breathing machine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)—rare diseases where the immune system attacks blood vessels
- Blood tests show ANCA antibodies (specifically PR3 or MPO), which confirm the diagnosis
- You have bleeding in your lungs (diffuse alveolar hemorrhage) and are currently on mechanical ventilation (breathing machine)
- Your disease is either newly diagnosed or has come back, and is considered severe by your doctor
- You have not received avacopan in the last 5 days and have not had a severe allergic reaction to it before
- Your liver function tests are mostly normal (unless liver problems are from the vasculitis itself)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication called avacopan for people with active ANCA-associated vasculitis (GPA or MPA). It’s for those who need strong treatment to control their disease and aims to see if avacopan works as well as standard therapies.
This trial tests if adding avacopan to standard treatments (rituximab or cyclophosphamide plus steroids) helps patients with severe kidney inflammation from a type of vasculitis. It may offer a new option for preserving kidney function.
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
This study looks at how well the drug avacopan works for people with a rare blood vessel disease called ANCA-associated vasculitis. It aims to help patients who are starting this treatment by tracking real-world results.
This study looks at the long-term safety and effectiveness of avacopan in people with certain types of vasculitis (GPA or MPA). It may help doctors understand how well the medicine works over time.
This trial tests if avacopan, a targeted anti-inflammatory drug, can safely treat a severe form of IgA nephropathy (IgAN) where small crescents form in the kidney filters. It may help reduce protein leakage and preserve kidney function.
Hear when a new Diffuse Alveolar Hemorrhage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.